Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr-Jun;13(2):64-67.
doi: 10.14797/mdcj-13-2-64.

Cardiovascular Disease in Acromegaly

Morali D Sharma  1 , Anh V Nguyen  1 , Spandana Brown  1 , Richard J Robbins  1
Affiliations
Review

Cardiovascular Disease in Acromegaly

Morali D Sharma et al. Methodist Debakey Cardiovasc J. 2017 Apr-Jun.

Abstract

In patients with acromegaly, chronic excess of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) leads to the development of acromegalic cardiomyopathy. Its main features are biventricular hypertrophy, diastolic dysfunction, and in later stages, systolic dysfunction and congestive heart failure. Surgical and/or pharmacological treatment of acromegaly and control of cardiovascular risk factors help reverse some of these pathophysiologic changes and decrease the high risk of cardiovascular complications.

Keywords: acromegaly; arrhythmia; cardiomyopathy; coronary artery disease; heart failure; hypertension; valvular heart disease.

PubMed Disclaimer

Conflict of interest statement

The authors have completed and submitted the Methodist DeBakey Cardiovascular Journal Conflict of Interest Statement and none were reported.

Figures

Figure 1.
Figure 1.
Pathophysiology of acromegalic cardiomyopathy. OSA: obstructive sleep apnea
See this image and copyright information in PMC

References

    1. Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009. November 2; 119 11: 3189– 202. - PMC - PubMed
    1. Saccà L, Napoli R, Cittadini A.. Growth hormone, acromegaly, and heart failure: an intricate triangulation. Clin Endocrinol (Oxf). 2003. December; 59 6: 660– 71. - PubMed
    1. Troncoso R, Ibarra C, Vicencio JM, Jaimovich E, Lavandero S.. New insights into IGF-1 signaling in the heart. Trends Endocrinol Metab. 2014. March; 25 3: 128– 37. - PubMed
    1. Lu C, Schwartzbauer G, Sperling MA, . et al. Demonstration of direct effects of growth hormone on neonatal cardiomyocytes. J Biol Chem. 2001. June 22; 276 25: 22892– 900. - PubMed
    1. Timsit J, Riou B, Bertherat J, . et al. Effects of chronic growth hormone hypersecretion on intrinsic contractility, energetics, isomyosin pattern, and myosin adenosine triphosphatase activity of rat left ventricle. J Clin Invest. 1990. August; 86 2: 507– 15. - PMC - PubMed

MeSH terms

LinkOut - more resources